Literature DB >> 11135301

Cancer cachexia: a therapeutic approach.

J M Argilés1, S H Meijsing, J Pallarés-Trujillo, X Guirao, F J López-Soriano.   

Abstract

Cancer cachexia is a complex syndrome which occurs in more than two-thirds of patients who die with advanced cancer. The main components of this pathological state are anorexia and metabolic abnormalities such as glucose intolerance, fat depletion, and muscle protein catabolism among others. The aim of the present study is to review the different therapeutic approaches that have been designed to fight and counteract cancer cachexia.

Entities:  

Mesh：

Year:  2001        PMID： 11135301     DOI： 10.1002/1098-1128(200101)21:1<83::aid-med4>3.0.co;2-1

Source DB:  PubMed          Journal:  Med Res Rev        ISSN： 0198-6325            Impact factor:   12.944


  16 in total

1.  Decrease of serum carnitine levels in patients with or without gastrointestinal cancer cachexia.

Authors:  Mariano Malaguarnera; Corrado Risino; Maria Pia Gargante; Giovanni Oreste; Gloria Barone; Anna Veronica Tomasello; Mario Costanzo; Matteo Angelo Cannizzaro
Journal:  World J Gastroenterol       Date:  2006-07-28       Impact factor: 5.742

Review 2.  Anorexia-Cachexia syndrome in cancer: implications of the ubiquitin-proteasome pathway.

Authors:  Carlos Camps; Vega Iranzo; Roy M Bremnes; Rafael Sirera
Journal:  Support Care Cancer       Date:  2006-07-04       Impact factor: 3.603

3.  Serum cytokine profiles in patients with prostate carcinoma.

Authors:  Eri Tazaki; Nobuaki Shimizu; Ryota Tanaka; Masakazu Yoshizumi; Hiroshi Kamma; Shigeru Imoto; Tomoyuki Goya; Kunihisa Kozawa; Atsuyoshi Nishina; Hirokazu Kimura
Journal:  Exp Ther Med       Date:  2011-06-16       Impact factor: 2.447

Review 4.  Cancer cachexia, mechanism and treatment.

Authors:  Tomoyoshi Aoyagi; Krista P Terracina; Ali Raza; Hisahiro Matsubara; Kazuaki Takabe
Journal:  World J Gastrointest Oncol       Date:  2015-04-15

Review 5.  New drugs for the anorexia-cachexia syndrome.

Authors:  Mellar P Davis
Journal:  Curr Oncol Rep       Date:  2002-05       Impact factor: 5.075

6.  Cachexia worsens prognosis in patients with resectable pancreatic cancer.

Authors:  Jeannine Bachmann; Mathias Heiligensetzer; Holger Krakowski-Roosen; Markus W Büchler; Helmut Friess; Marc E Martignoni
Journal:  J Gastrointest Surg       Date:  2008-03-18       Impact factor: 3.452

7.  Lymphosarcoma-induced alterations in hepatic adrenergic receptors: implications to the hypoglycemia of cancer cachexia.

Authors:  Susan J Hemmings; Thomas R Wilson
Journal:  Mol Cell Biochem       Date:  2003-08       Impact factor: 3.396

8.  RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid.

Authors:  Todd M Morgan; Tiffany E M Pitts; Ted S Gross; Sandra L Poliachik; Robert L Vessella; Eva Corey
Journal:  Prostate       Date:  2008-06-01       Impact factor: 4.104

Review 9.  Regulation of IGF-I function by proinflammatory cytokines: at the interface of immunology and endocrinology.

Authors:  Jason C O'Connor; Robert H McCusker; Klemen Strle; Rodney W Johnson; Robert Dantzer; Keith W Kelley
Journal:  Cell Immunol       Date:  2008-03-05       Impact factor: 4.868

10.  Association of interleukin-8 with cachexia from patients with low-third gastric cancer.

Authors:  Bo Song; Dianliang Zhang; Shuchun Wang; Hongmei Zheng; Xinxiang Wang
Journal:  Comp Funct Genomics       Date:  2009-11-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.